ACTIVAERO AND CHIESI ENTER INTO RESEARCH COLLABORATION FOR NOVEL DRUG DEVICE COMBINATION IN CYSTIC FIBROSIS
(Thomson Reuters ONE) -
Activaero GmbH /
ACTIVAERO AND CHIESI ENTER INTO RESEARCH COLLABORATION FOR NOVEL DRUG DEVICE
COMBINATION IN CYSTIC FIBROSIS
. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Gemuenden/Wohra, Germany, September 09, 2013 - Activaero GmbH, the therapeutic
area specialist for respiratory diseases focusing on novel, pharmacoeconomically
meaningful treatment solutions for severe lung diseases, today announced that it
has entered into a research collaboration with Chiesi Farmaceutici S.p.A. The
companies are going to jointly evaluate the potential of a novel drug device
combination product using Activaero's proprietary FAVORITE inhalation approach
and Chiesi's pharmaceutical agent to create a highly mobile and effective
treatment solution for Cystic Fibrosis. Chiesi already has an established
presence in the Cystic Fibrosis field. The Company obtained approval and markets
directly or through partners its proprietary inhaled tobramycin solution
(Bramitob®/Bethkis®, 300mg/4ml UDV) in several countries worldwide, including
the United States.
Under the terms and conditions of the collaboration agreement, Activaero
provides Chiesi with its flow and volume regulated inhalation technology
(FAVORITE) incorporated in a customized device solution. Such a solution allows
for optimum drug distribution across the entire lung importantly including the
small airways. This most distal region of the lung is typically not accessible
with standard nebulizer systems due to the obstructions caused by scarred tissue
and mucus in the lungs of Cystic Fibrosis patients. The first part of the
research work is planned to be completed by the end of 2013. Financial details
of the collaboration were not disclosed.
"This exciting research collaboration represents further validation for our
proprietary FAVORITE inhalation approach by one of the pioneers in the
respiratory arena", commented Gerhard Scheuch, Founder and Chief Executive
Officer of Activaero GmbH. "We are highly optimistic that this program can
provide a significantly improved treatment solution for Cystic Fibrosis, a
detrimental disease with a high unmet medical need."
"The FAVORITE inhalation approach is highly promising to achieve optimal lung
deposition rates with lower drug doses and, ultimately, a better therapeutic
outcome in the treatment of Cystic Fibrosis. We are looking forward to work with
our new partner Activaero on this promising project", said Paolo Chiesi, Vice
President and R&D Director of the Chiesi Group.
About Cystic Fibrosis
Cystic Fibrosis (CF), also known as mucoviscidosis, is one of the most common
genetic disorders amongst Caucasians. The disease is inherited recessively with
an improved but still rather low life expectancy with a median age of currently
33.4 years according to the World Health Organization. CF leads to chronic
inflammations of the respiratory tract and also affects other organs, such as
the digestive tract, liver, sweat glands and reproductive organs. Symptoms
include, heavily salty-tasting sweat, coughing similar to whooping cough, severe
bronchitis and pneumonia, an increased production of tough an viscous mucus that
leads to frequent bacterial infections as well as disturbed digestions and male
sterility. Most patients die from cardiorespiratory complications caused by
those symptoms.
About FAVORITE
FAVORITE is Activaero's proprietary, clinically and commercially proven
inhalation approach to effectively treat severe respiratory and pulmonary
diseases. FAVORITE actively regulates inspiration flow and inhalation volume. By
guiding, controlling and supporting the patient's breathing, optimal inhalation
patterns are created. Using FAVORITE, inhaled drugs can be selectively targeted
to pre-defined lung regions hence unlocking completely new opportunities for
novel aerosol therapies.
About Activaero
Activaero is a therapeutic area specialist developing new, pharmacoeconomically
meaningful treatment solutions for patients suffering from severe respiratory
diseases, including Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic
Fibrosis (CF), Idiopathic Pulmonary Fibrosis (IPF) and Pulmonary Hypertension.
Activaero was founded in 1998 in Germany and is a privately held company with
offices in Germany near Frankfurt and Munich as well as in Dublin, Ohio (USA).
www.activaero.de
About Chiesi Farmaceutici
Founded in 1935 in Parma, Italy, Chiesi Farmaceutici currently has 25 affiliates
worldwide and markets its therapeutics in over 60 countries. Chiesi's
manufacturing plants in Parma, Blois (France) and Santana de Parnaiba (Brazil),
and R&D centers in Parma, Paris, Rockville (USA) and Chippenham (UK) integrate
their efforts to advance the Group's pre-clinical, clinical and registration
programs. At the end of 2012, the Chiesi Group's total staff stood at over
3,800 people, more than 350 of whom are dedicated to R&D. The main areas of
activity are in respiratory therapeutics and specialist medicine areas.
www.chiesigroup.com
Contact us:
Activaero GmbH Media Contact
Christian Pangratz Anne Hennecke
Chief Business Officer MC Services AG
t: +49-89-897969-65 t: +49-89-210228-18
e: christian.pangratz(at)activaero.de e: anne.hennecke(at)mc-services.eu
www.activaero.com
Chiesi Group
Massimo Zaninelli
Communication Advisor
t: +39 (0521) 279084
e: m.zaninelli(at)chiesi.com
Press release (PDF):
http://hugin.info/156033/R/1727896/576944.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Activaero GmbH via Thomson Reuters ONE
[HUG#1727896]
Unternehmensinformation / Kurzprofil:
Datum: 09.09.2013 - 09:00 Uhr
Sprache: Deutsch
News-ID 294484
Anzahl Zeichen: 6857
contact information:
Town:
Gemuenden/Wohra
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 102 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ACTIVAERO AND CHIESI ENTER INTO RESEARCH COLLABORATION FOR NOVEL DRUG DEVICE COMBINATION IN CYSTIC FIBROSIS"
steht unter der journalistisch-redaktionellen Verantwortung von
Activaero GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
